By Drug Target Review2025-09-29T08:30:50
New research highlights how cancer hijacks the unfolded protein response (UPR) in bone cells – potentially allowing for the development of therapies that target this pathway to prevent fractures.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2023-03-02T13:57:58
Sponsored by Cell Signaling Technology
2024-02-01T12:06:43
Sponsored by Leica Microsystems
2023-05-10T11:18:16
Sponsored by Revvity
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2024-02-06T08:57:06
Sponsored by bit.bio
Site powered by Webvision Cloud